

1 **Molecular Epidemiology of African Sleeping Sickness**

2

3 **GEOFF HIDE^a AND ANDREW TAIT^b**

4

5 ^a*Centre for Parasitology and Disease, Biomedical Sciences Research Institute, School of*
6 *Environment and Life Sciences, University of Salford, Salford, UK, M5 4WT*

7

8 ^b*Faculty of Veterinary Medicine, Division of Infection and Immunity, University of Glasgow,*
9 *Bearsden Road, Glasgow, G61 1QH, Scotland, U.K.*

10

11 Corresponding Author:

12 Geoff Hide

13 Centre for Parasitology and Disease, Biomedical Sciences Research Institute, School of
14 Environment and Life Sciences, University of Salford, Salford, UK, M5 4WT

15 Telephone No: 0161 295 3371

16 Fascimile No: 0161 295 5015

17 E-mail No: g.hide@salford.ac.uk

18

19

20 Running title: Molecular epidemiology of African sleeping sickness

21

22 Keywords: African trypanosomiasis; *Trypanosoma brucei*; sleeping sickness; molecular
23 epidemiology; epidemics; microsatellites; genetics; population structure

24

25

1 SUMMARY

2 Human sleeping sickness in Africa, caused by *Trypanosoma brucei* spp. raises a number of
3 questions. Despite the widespread distribution of the tsetse vectors and animal
4 trypanosomiasis, human disease is only found in discrete foci which periodically give rise to
5 epidemics followed by periods of endemicity. A key to unravelling this puzzle is a detailed
6 knowledge of the etiological agents responsible for different patterns of disease – knowledge
7 that is difficult to achieve using traditional microscopy. The science of molecular
8 epidemiology has developed a range of tools which have enabled us to accurately identify
9 taxonomic groups at all levels (species, subspecies, populations, strains and isolates). Using
10 these tools, we can now investigate the genetic interactions within and between populations
11 of *Trypanosoma brucei* and gain an understanding of the distinction between human- and
12 nonhuman-infective sub species. In this review, we discuss the development of these tools,
13 their advantages and disadvantages and describe how they have been used to understand
14 parasite genetic diversity, the origin of epidemics, the role of reservoir hosts and the
15 population structure. Using the specific case of *T.b.rhodesiense* in Uganda, we illustrate how
16 molecular epidemiology has enabled us to construct a more detailed understanding of the
17 origins, generation and dynamics of sleeping sickness epidemics.

1 INTRODUCTION

2

3 Human sleeping sickness in Africa is a puzzling disease. It is caused by the parasite
4 *Trypanosoma brucei* (see table 1). Despite the widespread distribution of the tsetse vectors
5 and animal trypanosomiasis, human disease is found in very specific foci and appears as
6 epidemics followed by periods of endemicity (reviewed in Hide, 1999). The locations of these
7 foci are very stable over time but occasionally new epidemics emerge in new localities. For
8 example, the Busoga focus of Uganda has had epidemics recorded from 1900 to the present
9 day while a new epidemic has emerged in the nearby Soroti region – an area free of sleeping
10 sickness prior to 1998 (Welburn *et al.*, 2001). An understanding of the factors which cause
11 these epidemics could clearly lead to an understanding of how to eradicate the disease.
12 Sleeping sickness was one of the earliest examples of the application of molecular
13 epidemiology to a parasitic disease and, as will be seen, some important insights have been
14 made into the origins and dynamics of these epidemics. In this review, we will trace the
15 development of molecular epidemiological approaches with a particular emphasis on African
16 sleeping sickness. As the journal “Parasitology” has played a significant role in publishing
17 these developments it is an appropriate topic for the centenary issue.

18

19 MOLECULAR EPIDEMIOLOGY

20 The molecular epidemiology of parasites describes the application of DNA based techniques
21 to the understanding of parasite epidemiology and diversity (Hide & Tait, 1991). The
22 approach was prompted by an emerging understanding that parasites could not be easily
23 packaged into groups of organisms that produced defined diseases in defined hosts. Instead,
24 there were complex epidemiological cycles involving multiple hosts, sometimes multiple

1 diseases, reservoir hosts, specific strains, emerging drug resistance, genetic exchange
2 between strains and even the apparent emergence of new parasite species. Thus tools were
3 needed which could be used to gain a higher level of resolution than morphology in defining
4 the organisms involved. In fact, the discipline of molecular epidemiology strictly emerged
5 from several earlier strands of research. Principally this was the use of phenotypic
6 approaches such as isoenzyme (or allozyme) analysis as a tool to study the epidemiology of
7 parasitic infections. One of the key epidemiological questions in parasitology is determining
8 the correct identity (diagnosis) and taxonomic level of a given parasite (eg. species,
9 subspecies, strains, variants). This has often proved challenging especially in the case of
10 microscopic parasites (e.g. parasitic protozoa) where morphological distinctions are not
11 easily identified. Two linked problems exist – defining the scope of a taxonomic unit and
12 establishing unambiguous markers for each unit. The scope of a taxonomic unit could be
13 relatively easily established in the absence of any form of gene exchange between units such
14 as occurs in clearly distinct species or clonally reproducing parasites. However in earlier
15 studies the precise identity of parasitic species or the role of gene exchange was often not
16 known. An inability to clearly define taxonomic units therefore makes it difficult to identify
17 markers that can be used diagnostically to distinguish that taxonomic unit. There is
18 unfortunately a degree of circularity in the problem. There are two levels of identification
19 needed: (1) diagnosis – generally referring to diagnostic tools capable of discriminating to the
20 species level and defining a particular association between causative agent and disease and
21 (2) epidemiological tools – generally referring to markers that can be used at the sub-species
22 or strain level to investigate detailed interactions within parasite transmission cycles. This
23 problem of circularity in developing appropriate markers can be overcome by using
24 independent markers that are not linked to the, often very subjective, medical criteria by

1 which parasites were traditionally classified. DNA based molecular methods offered a
2 potential solution to these problems.

3

4 FROM BIOCHEMICAL TO MOLECULAR EPIDEMIOLOGY

5

6 The advent of protein based technologies such as gel electrophoretic separation of
7 isoenzymes (allozymes) enabled distinction of morphologically identical organisms and could
8 be used as a tool for genetic studies. These approaches were initially used with the free-
9 living protozoa both as markers for studying genetic exchange and for defining species
10 (previously defined as syngens) as illustrated by work with *Paramecium aurelia* (Tait, 1970a;
11 Tait, 1970b). Key centres in Edinburgh, London and subsequently Bristol then applied these
12 approaches to investigating the genetics and taxonomy of the medically important protozoa,
13 *Plasmodium* and *Trypanosoma*. For example these approaches were used for identifying
14 different levels of taxonomic units (eg species, subspecies and strains) in *Plasmodium*
15 (Carter & Walliker, 1975) and *Trypanosoma* spp (Kilgour and Godfrey, 1973; Miles *et al.*,
16 1977; Godfrey, 1978; Gibson *et al.*, 1978; Gibson *et al.*, 1980; Tait *et al.*, 1984, 1985).
17 Furthermore, using these techniques, genetic exchange was shown to occur in *Plasmodium*
18 spp (Walliker *et al.*, 1971, 1973) and *Trypanosoma* spp (Tait, 1980; Gibson *et al.*, 1980; Jenni
19 *et al.*, 1986; Gibson *et al.*, 1989).

20 When used to analyse the African trypanosomes causing human sleeping sickness, these
21 approaches revealed a complex taxonomic situation. The classical taxonomy described three
22 subspecies, *Trypanosoma brucei brucei*, (non-human infective) *Trypanosoma brucei*
23 *rhodesiense* (East African, human infective) and *Trypanosoma brucei gambiense* (West
24 African, human infective). Multilocus enzyme electrophoresis (MLEE) studies revealed that

1 there were clearly subgroups or strains within both *T.b.gambiense* and *T.b.rhodesiense* as
2 well as a high degree of variation between isolates of *T.b.brucei* (Gibson *et al.*, 1980; Tait *et*
3 *al.*, 1984, 1985). Furthermore, these studies showed that different levels of taxonomy
4 appeared to be operating – the genetic relationships showed that *T.b.gambiense* appeared to
5 behave like a separate subspecies while *T.b.rhodesiense* appeared to be a host range
6 variant of *T.b.brucei*.

7 It was becoming apparent that the question of what defines a species in parasitic protozoa
8 (and other micro-pathogens) was a complex one to address. Traditionally, the species
9 concept is based on presence or absence of genetic exchange between taxonomic units. In
10 the case of *T.brucei* spp, the extent of the occurrence of genetic exchange in natural
11 populations was unclear. Tibayrenc *et al.*, 1990 conducted a reanalysis of MLEE data from a
12 wide range of pathogens including *T.brucei* and *Plasmodium* and proposed a clonal theory,
13 based on a range of measures such as high levels of heterozygosity, linkage disequilibrium
14 and over representation of particular genotypes. In the case of *T.b.rhodesiense* there was
15 evidence for clonality but the results with *T.b.brucei* were less convincing. Further analysis of
16 a large collection of isolates from across Africa (Mathieu-Daude & Tibayrenc, 1994) was
17 interpreted as showing limited genetic exchange although geographical sub-structuring could
18 be an explanation given the diversity of the origins of the strains. These conclusions
19 conflicted with published data showing the existence of genetic exchange (eg Tait and
20 Turner, 1990). Analysis of a large collection of isolates from the Lambwe Valley focus, in
21 Kenya, provided a partial resolution of the debate by showing that the population had an
22 epidemic population structure (Maynard-Smith *et al.*, 1993) i.e. that is there was underlying
23 genetic exchange masked by the local expansion of a small number of genotypes. Further
24 analysis of populations from Cote d'Ivoire, Zambia and Busoga, Uganda, (Stevens and

1 Tibayrenc, 1995) showed a diversity of population structures with evidence for clonality in
2 some populations but an epidemic structure in others (Uganda). This diversity was also
3 illustrated by MLEE analysis of sympatric stocks collected during a sleeping sickness
4 epidemic in Tororo, Uganda (Figure 1). In this study, it was demonstrated that the population
5 structure of the *T.b.brucei* stocks appeared to conform to a random mating population
6 structure while the population structure of *T.b.rhodesiense* was recognized as epidemic (Hide
7 *et al.*, 1994). The debate over the role of genetic exchange in *T.brucei* was not fully resolved
8 using MLEE.

9 MLEE is a highly informative technique and enabled epidemiological analyses to be based on
10 a genetic interpretation, with the essential conclusions for African trypanosomes remaining
11 unchallenged today. However, these methods require relatively large quantities of pure
12 parasite material and so are cumbersome for large scale epidemiological analysis. Initially,
13 blood from patients and animals had to be isolated, followed by several passages through
14 mice (or in culture) and further mouse amplification to produce enough material for analysis.
15 In some cases, the Kit for In Vitro Isolation (KIVI) of trypanosomes has been used to isolate
16 trypanosomes (Truc *et al.*, 1992). During these processes, cloning from individual
17 trypanosomes was also often necessary with several years work required to analyse an
18 appropriately sized sample set. An additional problem associated with these methods is the
19 potential of the methods to select for particular types of trypanosomes, such as those better
20 adapted to growth in mice, and thereby introduce bias into the distribution of parasites
21 recovered (Koffi *et al.*, 2007).

22 Initially, DNA technology was focussed on developing diagnostic tools to identify
23 *Trypanosoma* species. As it is the subject of another review in this issue (Gibson, 2009), it
24 will not be considered further here and we will consider the development of DNA based tools

1 for measuring intraspecific variation (Table 2). Initial DNA studies on intraspecific variation in
2 *T.brucei* were based on analysis of restriction enzyme site variation in the kinetoplast DNA
3 (Borst *et al.*, 1981). However with limited stocks available and a relatively small number of
4 restriction enzyme sites covered, it was not possible to discriminate between the three
5 subspecies. A larger scale analysis (Gibson *et al.*, 1985) however demonstrated that a
6 difference could be detected in stocks originating from East and West Africa. Restriction
7 Fragment Length Polymorphism (RFLP) of VSG antigen genes and numerical taxonomy,
8 based on those RFLPs, revealed that *T.b.gambiense* was quite distinct from *T.b.rhodesiense*
9 or *T.b.brucei* but that the latter two subspecies could not be distinguished (Paindavoine *et al.*,
10 1986). However, it was discovered that two forms of *T.b.gambiense* existed (Paindavoine *et*
11 *al.*, 1986; 1989) one of which was probably the classical *T.b.gambiense* (Type 1) and one
12 which has been called either non-gambiense or Type 2 or “Bouafle” (Gibson, 1986;
13 Paindavoine *et al.*, 1989; Gibson, 2007). This latter group is relatively rare and may constitute
14 a variant of *T.b.brucei* that has acquired human infectivity (Gibson, 2007). RFLP methods
15 were developed using repetitive DNA sequences including the ribosomal RNA genes to
16 investigate RFLP variation using multiple loci (Hide *et al.*, 1990). Although these data could
17 not be interpreted genetically and could not detect mixtures of trypanosomes, they offered a
18 highly discriminatory approach to “fingerprinting” trypanosome isolates. The RFLP data
19 combined with numerical taxonomy clearly distinguished the two types of *T.b.gambiense* and
20 showed that the Type 2 appeared to be a subset of West African *T.b.brucei* strains (Hide *et*
21 *al.*, 1990). Furthermore, comparison of two *T.b.rhodesiense* foci in Zambia and Uganda
22 showed that there were two genetically distinct groups in the two foci (Hide *et al.*, 1991). A
23 detailed analysis of the 1988 sleeping sickness epidemic in Tororo, Uganda, showed that the
24 human isolates (ie *T.b.rhodesiense*) were genetically homogeneous and could be clearly

1 distinguished from non-human isolates (ie *T.b.brucei*) by numerical taxonomy (Hide *et al.*,
2 1994) using RFLP data. Furthermore, the *T.b.rhodesiense* stocks were found to be frequent
3 in cattle and were closely related to isolates from previous epidemics since the 1960s in that
4 region. Combining molecular and traditional epidemiological data it was shown that humans
5 were five times more likely to acquire sleeping sickness via cattle than from other humans
6 (Hide *et al.*, 1996), thus demonstrating the importance of cattle as a reservoir for sleeping
7 sickness during an epidemic (Hide, 1999). Comparison of epidemic and endemic areas of
8 sleeping sickness (Hide *et al.*, 1998) and areas free of sleeping sickness (Hide *et al.*, 2000)
9 revealed the presence of the same human infective strains in patients, cattle and tsetse
10 suggesting that the presence of a human infective strain was not the only factor determining
11 whether an epidemic developed.

12 It was observed that *T.b.rhodesiense* isolates circulating in the Tororo region of Uganda were
13 genetically homogeneous whilst the sympatric *T.b.brucei* isolates were much more diverse
14 (Hide *et al.*, 1994). This raised the question as to the contribution of genetic exchange in
15 “field” populations of trypanosomes. High levels of genetic exchange would facilitate the
16 “spread” of phenotypes, such as human infectivity and drug resistance, potentially into new
17 populations and could possibly explain the emergence of new epidemics. This collection of
18 stocks offered an opportunity to investigate this question since they were isolated at the
19 same place and time. However, as suitable DNA based techniques were not available, it was
20 necessary to resort to MLEE analysis to show that genetic exchange was frequent in
21 *T.b.brucei* but epidemic in *T.b.rhodesiense* (Hide *et al.*, 1994).

22 This suggested that genetic exchange could contribute to the genetic variation in
23 trypanosome isolates in the field and importantly could contribute to the epidemiology of the
24 disease. Two problems beset further analysis of these questions. Firstly, the inability to

1 genetically interpret multilocus RFLP markers and, secondly, despite DNA based methods
2 providing higher levels of resolution, the requirement for sufficient pure parasite material for
3 analysis.

4

5 PCR BASED MOLECULAR EPIDEMIOLOGICAL TOOLS

6 The advent of PCR to amplify and identify DNA at source or from small amounts of parasite
7 material – such as a single trypanosome (Macleod *et al.*, 1997; Cox *et al.*, 2005) - offered
8 tremendous advantages particularly in the area of diagnosis. In terms of epidemiological
9 analysis, where multilocus analysis was clearly important, this was more difficult. Some
10 single locus typing such as PCR-RFLP were found to be of limited use (Tilley & Hide, 2001).
11 Random Amplification of Polymorphic DNA (RAPD) analysis was one of the initial solutions to
12 PCR amplification of multiple loci (Mathieu-Daude *et al.*, 1995; Stevens *et al.*, 1995). This
13 technique relied on the use of a short single PCR primer which randomly annealed to the
14 DNA sample, a banding pattern was produced for each stock and numerical taxonomy used
15 to assess the relatedness of stocks with each other. This was a good multilocus approach,
16 useful with small amounts of DNA, which probably sampled the full extent of the genome
17 rather than being restricted to certain genes or parts of the genome. However, this method is
18 highly susceptible to contaminating host or other DNA – bands will be generated from any
19 DNA template, it is not possible to interpret genetically and is unable to detect mixed
20 infections of trypanosomes. A similar approach, Amplified Fragment Length Polymorphism
21 (AFLP), uses PCR primers based on restriction enzyme sites to look for variation between
22 trypanosome stocks (Agbo *et al.*, 2002) and has the same advantages and disadvantages of
23 RAPD analysis. To overcome the problem of contaminating host DNA, a technique termed
24 MGE-PCR (Mobile Genetic Element PCR) was developed utilising the positional variation of

1 mobile genetic elements to detect genetic variation between parasite isolates (Hide & Tilley,
2 2001; Terry *et al.*, 2001; Tilley *et al.*, 2003). Using a single primer designed to be specific for
3 the repeat regions of the RIME mobile genetic element of *T.brucei*, amplification of bands
4 between adjacent RIME elements generates a banding pattern which varies from stock to
5 stock based on differences in the positions of RIME elements and so can be used to identify
6 groups of similar isolates by numerical taxonomy. This approach has the advantage that it is
7 PCR-based, specific to *T.brucei* DNA, multilocus, representative of a significant portion of the
8 genome and generates a single “fingerprint” for each isolate or stock. The disadvantages are
9 that it cannot detect mixed infections and it cannot be interpreted genetically.

10 The markers that offer the greatest prospects are the mini- and micro-satellite markers (eg
11 Macleod *et al.*, 1997; Biteau *et al.*, 2000). These short repeated sequences vary in length or
12 sequence between trypanosome strains and can be amplified and analysed by population
13 genetic methods (MacLeod *et al.*, 2001a). Such markers can be used to detect mixed
14 infections (MacLeod *et al.*, 1999; Koffi *et al.*, 2007), are highly specific and sensitive tools for
15 detection of *T.brucei* *ssp* and can be used without the need to amplify parasites in rodents
16 (Morrison *et al.*, 2007). The development of PCR based methods for detailed analysis of
17 trypanosome stocks has opened up many avenues of research. In the remainder of this
18 review we will focus on the contributions of these techniques to our understanding of the
19 diversity of trypanosome isolates in the field, the role of genetic exchange in the
20 epidemiology of sleeping sickness, the nature of human infective strains and the generation
21 of sleeping sickness epidemics.

22 Many studies have examined the diversity of *T.brucei* stocks obtained from field isolates.
23 What is clear is that the initial biochemical and molecular studies were correct in suggesting
24 substructuring within each of the subspecies *T.b.gambiense* and *T.b.rhodesiense*. Analyses

1 of stocks of *T.b.gambiense* Type 1 clearly show this group to be genetically highly
2 homogeneous within a focus and distinguishable from *T.b.brucei* or *T.b.rhodesiense* by
3 RAPD (Jamonneau *et al.*, 2002) microsatellite analysis (Biteau *et al.*, 2000; Jamonneau *et*
4 *al.*, 2002), minisatellite analysis (MacLeod *et al.*, 2001a; MacLeod 2001b; MacLeod 2001c),
5 MGE-PCR (Simo *et al.*, 2005) and AFLP (Simo *et al.*, 2008). In most cases, Type 1
6 *T.b.gambiense* has been shown to be genetically homogeneous despite differing symptoms
7 in humans being associated with identical parasite genotypes (Jamonneau *et al.*, 2002).
8 However, more detailed studies have revealed significant differences between isolates from
9 different foci within the Type 1 group (Truc *et al.*, 2002; Morrison *et al.*, 2008; Koffi *et al.*,
10 2009). Interestingly, a new group of *T.b.gambiense* was identified by micro- and mini-
11 satellites that was associated with asymptomatic disease in humans (Jamonneau *et al.*,
12 2004a). It is clear from the microsatellite studies that *T.b.gambiense* Type 1 is clonal and
13 very limited, if any, genetic exchange occurs in the field (Morrison *et al.*, 2008; Koffi *et al.*,
14 2009).
15 The clonal nature of *T.b.gambiense* has allowed it to be clearly identified and shown to be
16 zoonotic. Early isoenzyme studies demonstrated its presence in dogs, pigs, bovines and wild
17 game (Mehlitz *et al.*, 1982) suggesting a possible animal reservoir. Recent research using
18 PCR based tools have shown that pigs (Njiokou *et al.*, 2006; Simo *et al.*, 2006) and wild
19 fauna (Njiokou *et al.*, 2006) have the potential to be animal reservoirs. Although in another
20 study, using microsatellite analysis, pigs were not considered to be an active reservoir
21 (Jamoneau *et al.*, 2004b). It is also possible that untreated, parasitologically unconfirmed,
22 seropositive individuals could also act as a human reservoir (Garcia *et al.*, 2006; Checchi *et*
23 *al.*, 2008). In a clonal pathogen, such as *T.b.gambiense*, the lack of genetic exchange is

1 helpful since it ensures a reasonable level of stability and reproducibility in genetic markers
2 for use in epidemiological studies.

3 As with *T.b.gambiense*, minisatellite analysis has been used to investigate whether
4 *T.b.rhodesiense* is clonal (MacLeod *et al.*, 2000). When the sympatric stocks from Tororo,
5 Uganda (Hide *et al.*, 1994), were examined *T.b.rhodesiense* was found to be clonal
6 suggesting that little or no genetic exchange is occurring in this population (MacLeod *et al.*,
7 2000). This is in contrast with earlier MLEE studies, using the same stocks, that suggested it
8 was epidemic (Hide *et al.*, 1994) – that is, genetic exchange masked by the amplification of a
9 small number of genotypes. This discrepancy might be explained by the more detailed and
10 sophisticated analyses available using minisatellites.

11 However, as predicted by the earlier MLEE and RFLP studies, genetic differences between
12 different geographical populations can be clearly detected by minisatellite DNA analysis such
13 as between Uganda and Zambia (MacLeod *et al.*, 2001b) and using polymorphism in the
14 SRA (Serum Resistant Associated) gene between populations in Uganda and Malawi or
15 Zambia (Gibson *et al.*, 2002; McLean *et al.*, 2004).

16 The SRA gene (De Greef *et al.*, 1989) has been shown to be capable of transforming a non
17 human-infective *T.brucei* to a human-infective phenotype (Xong *et al.*, 1998). This gene is
18 present in all human-infective field samples from East Africa and absent in animal isolates
19 and has consequently been used as a diagnostic tool for *T.b.rhodesiense* (Welburn *et al.*,
20 2001; Gibson *et al.*, 2002). Although, this gene looks promising as the candidate gene
21 determining human infectivity in *T.brucei*, it is clearly absent from both *T.b.gambiense* Type 1
22 and 2 (Turner *et al.*, 2004) showing that there is more than one mechanism that determines
23 human infectivity. There is growing evidence to suggest that in at least some epidemics, such

1 as the 1998 epidemic in Soroti in Uganda, that the spread of trypanosomes expressing the
2 SRA gene may be responsible for the generation of epidemics (Welburn *et al.*, 2001).

3

4 MOLECULAR EPIDEMIOLOGY: THE ORIGINS AND DYNAMICS OF *TRYPANOSOMA* 5 *BRUCEI RHODESIENSE* SLEEPING SICKNESS EPIDEMICS

6 The 1988 Tororo sleeping sickness epidemic in Uganda resulted in a legacy of trypanosome
7 stocks isolated during an epidemic (Hide *et al.*, 1994). In addition to analysis by RFLP, they
8 have been analysed using minisatellite markers (MacLeod *et al.*, 2000), MGE-PCR (Tilley *et*
9 *al.*, 2003) and the SRA gene (Welburn *et al.*, 2001). A clear distinction has emerged between
10 the human infective stocks and non human-infective stocks in this region. The finding that
11 cattle are an important reservoir for human infective stocks (Hide *et al.*, 1996) has been
12 confirmed by more recent studies (Welburn *et al.*, 2001). Isolates collected from humans ten
13 years on from this epidemic have been shown by MGE-PCR to contain some identical
14 genotypes thus confirming the stability of genotypes within this focus (Tilley *et al.*, 2003). A
15 new epidemic started in December 1998 in Soroti, Uganda (Fevre *et al.*, 2001), and is
16 currently ongoing and spreading north and west (Fevre *et al.*, 2005). Based on the evidence
17 that cattle are an important reservoir for sleeping sickness, it has been postulated that cattle
18 infected with human-infective *T.brucei* were imported from the Tororo District into Soroti
19 (Fevre *et al.*, 2001). These cattle were then fed upon by local tsetse, passed onto the local
20 people and the epidemic started. Statistical analysis of the location of sleeping sickness
21 cases in relation to the Soroti cattle market (Fevre *et al.*, 2001) and the presence of SRA
22 positive *T.brucei* isolated from the cattle at this market has supported this view (Welburn *et*
23 *al.*, 2001). Other studies conducted on *T.brucei* isolates collected from Soroti suggest that
24 they have a different clinical disease profile (eg more chronic presentation) to isolates

1 collected in Tororo and also the corresponding microsatellite profiles were found to be
2 different (McLean *et al.*, 2007). This supports the view that, although some of the isolates
3 have probably originated in Tororo, there may be other origins of these *T.brucei* isolates.
4 These results clearly show that the importation of cattle from a high risk area may have been
5 responsible for the generation of this new epidemic. It also shows the importance of tracking
6 cattle movements particularly from high risk areas, such as Tororo, and the identification of
7 the geographical locations of high risk areas.

8 Based on the extensive molecular epidemiological data from Uganda, it is possible to
9 formulate a model of how sleeping sickness foci are generated and how epidemics develop.
10 It is clear from the data that foci, such as the Busoga focus, must have the presence of a
11 human infective *T.brucei* strain ("*T.b.rhodesiense*"). Molecular epidemiological studies
12 suggest that this may be a single predominant clonal strain which remains stable over time
13 (although multiple clonal strains could also be present). New epidemics can be generated by
14 the influx of a human strain into an area previously occupied by only animal strains. This
15 could be by the importation of a reservoir species, such as cattle, infected with a human
16 strain. Local socio-political customs or events may determine the amplitude and duration of
17 the epidemic. Despite having a wide antigenic repertoire, clonality will ensure that any given
18 *T.b.rhodesiense* strain will have reduced genetic variability. Consequently, with time, a local
19 human population will become immune/less susceptible or subjected to health interventions
20 causing the epidemic to decline. On entering a naïve population, such as Soroti, clonal
21 human strains would spread quickly. It is clear that different foci appear to have genetically
22 different human strains (*T.b.rhodesiense* or *T.b.gambiense*) which could be generated either
23 by the SRA gene being introduced into a new genetic background or by the introduction of
24 one of the other mechanisms of human infectivity emerging in a previously non human-

1 infective strain. This mechanism could involve genetic exchange between a non human- and
2 a human-infective strain. With time and selection through humans, emergent human strains
3 might become established and generate new foci. The data suggest that in the field genetic
4 exchange occurs but is masked by the epidemic spread of a small number of strains. The
5 relatively small numbers of human infective strains, the relatively small number of foci and
6 the long term stability of foci might suggest that there is a minimal effect of genetic exchange
7 in generating new human strains and foci. However, in practice, the generation of even a
8 single new focus creates a significant health issue. Important questions arise from this model.
9 Are there low frequencies of genetic exchange generating new human-infective strains or is
10 the generation of new human-infective strains by genetic exchange frequent but fixation of
11 those strains within the population (to produce a focus) infrequent? Also, given the relatively
12 limited data from foci in Zambia, Tanzania, Malawi and Mozambique, are the conclusions
13 from the Ugandan studies typical for *T.b.rhodesiense*? As can be seen from this review, the
14 molecular tools are now available to address such questions.

15 As with any model, this one generates more questions than it answers. We have come along
16 way to understanding the generation of sleeping sickness epidemics but further questions
17 need to be addressed. The future of molecular epidemiology will be based on our increasing
18 ability to be able to conduct large scale epidemiological studies which will involve carefully
19 controlled sampling strategies, application of high throughput whole genome technologies for
20 both host and parasite, development of Single Nucleotide Polymorphism (SNP) chips,
21 development of bioinformatics tools and integration with mathematical models of disease
22 transmission. These approaches and technologies provide opportunities for the future and
23 offer the prospect of addressing some of the questions raised in this review.

24

1 ACKNOWLEDGEMENTS

2 We would like to acknowledge all of our colleagues who have contributed to the studies we
3 have reviewed here. While we have tried to provide appropriate coverage in this review, we
4 acknowledge that a great deal of important work could not be included here for reasons of
5 space.

6

1 REFERENCES

2

3 AGBO, E.E.C., MAJIWA, P.A.O., CLAASSEN, H.J. and TE PAS, M.F.W. (2002) Molecular
4 variation of *Trypanosoma brucei* subspecies as revealed by AFLP fingerprinting. *Parasitology*
5 **124**, 249-358.

6

7 BITEAU, N., BRINGAUD, F., GIBSON, W.C., TRUC, P. and BALTZ, T. (2000)
8 Characterization of *Trypanozoon* isolates using a repeated coding sequence and
9 microsatellite markers
10 *Molecular and Biochemical Parasitology* **105**,185-201.

11

12 BORST, P., FASE-FOWLER, F., and GIBSON W.C. (1981). Quantitation of genetic
13 differences between *Trypanosoma brucei gambiense*, *rhodesiense* and *brucei* by restriction
14 enzyme analysis of kinetoplast DNA. *Molecular and Biochemical Parasitology* **3**:117-131.

15 .

16 CARTER, R. and WALLIKER, D. (1975). New observations on the malaria parasites of
17 rodents of the Central African Republic - *Plasmodium vinckei petteri* subsp. nov. and
18 *Plasmodium chabaudi* Landau, 1965. *Annals of Tropical Medicine and Parasitology*. **69**,187-
19 96.

20

21 CHECCHI, F., FILIPE, J.A., BARRETT, M.P. and CHANDRAMOHAN, D. (2008). The
22 natural progression of gambiense sleeping sickness: what is the evidence? *PLoS*
23 *Neglected Tropical Diseases*. **2** 303.

24

1 COX, A., TILLEY, A., MCODEMBA, F., FYFE, J., HIDE, G. and WELBURN, S.C. (2005). A
2 PCR based assay for detection and differentiation of African trypanosome species in blood.
3 *Experimental Parasitology*, **111**, 24-29.

4

5 DE GREEF, C., IMBERECHTS, H., MATTHYSSENS, G., VAN MEIRVENNE, N., and
6 HAMERS, R. (1989). A gene expressed only in serum-resistant variants of *Trypanosoma*
7 *brucei rhodesiense*. *Molecular and Biochemical Parasitology*, **36**, 169-176.

8

9 FÈVRE, E.M., COLEMAN, P.G., ODIIT, M.D., MAGONA, J., WELBURN, S.C. and
10 WOOLHOUSE, M.E.J. (2001). The origins of a new sleeping sickness outbreak (caused by
11 *Trypanosoma brucei* infection) in eastern Uganda. *The Lancet* **358**, 625-628.

12

13 FÈVRE, E.M., PICOZZI, K., FYFE, J., WAISWA, C., ODIIT, M., COLEMAN, P.G. and
14 WELBURN S.C. (2005). A burgeoning epidemic of sleeping sickness in Uganda. *The Lancet*.
15 **366**, 745-747.

16

17 GARCIA, A., COURTIN, D., SOLANO, P., KOFFI, M. and JAMONNEAU, V. (2006). Human
18 African trypanosomiasis: connecting parasite and host genetics. *Trends in Parasitology* **22**,
19 405-409.

20

21 GIBSON, W.C. (1986). Will the real *Trypanosoma brucei gambiense* please stand up?
22 *Parasitology Today* **2**, 255-257.

23

1 GIBSON, W.C. (1989). Analysis of a genetic cross between *Trypanosoma brucei*
2 *rhodesiense* and *T. b. brucei*. *Parasitology*, **99**, 391-402.

3

4 GIBSON, W.C. (2009) Species-specific probes for the identification of the African tsetse-
5 transmitted trypanosomes. *Parasitology*. In Press (current volume).

6

7 GIBSON, W., MEHLITZ, D., LANHAM, S.M. and GODFREY, D.G. (1978). The identification
8 of *Trypanosoma brucei gambiense* in Liberian pigs and dogs by isoenzymes and by
9 resistance to human plasma. *Tropenmedezin und Parasitologie*, **29**, 335-45

10

11 GIBSON, W.C., MARSHALL, T.F. DE C. and GODFREY, D.G. (1980) Numerical analysis of
12 enzyme polymorphism. A new approach to the epidemiology and taxonomy of trypanosomes
13 of the genus *Trypanozoon*. *Advances in Parasitology* **18**, 175-245.

14

15 GIBSON, W., BORST, P. and FASE-FOWLER, F. (1985). Further analysis of intraspecific
16 variation in *Trypanosoma brucei* using restriction site polymorphisms in the maxi-circle of
17 kinetoplast DNA. *Molecular and Biochemical Parasitology*, **15**, 21-36

18

19 GIBSON, W.C., BACKHOUSE, T. and GRIFFITHS, A. (2002) The human serum resistance
20 associated gene is ubiquitous and conserved in *Trypanosoma brucei rhodesiense* throughout
21 East Africa. *Infection, Genetics and Evolution* **1**, 207–214.

22

23 GIBSON, W.C. (2007) Resolution of the species problem in African trypanosomes.
24 *International Journal for Parasitology*, **37**, 829 - 838.

1 GODFREY, D.G. (1978). Identification of economically important parasites. *Nature*, 273, 600-
2 604.
3
4 HIDE, G. (1999) The history of sleeping sickness in East Africa. *Clinical Microbiological*
5 *Reviews* **12**, 112-125.
6
7 HIDE, G., CATTAND, P., LE RAY, D., BARRY, J.D. and TAIT, A. (1990). The identification of
8 *T. brucei* subspecies using repetitive DNA sequences. *Molecular and Biochemical*
9 *Parasitology*, **39**, 213-226.
10
11 HIDE, G. and TAIT, A. (1991) The molecular epidemiology of parasites. *Experientia* **47**, 128-
12 142.
13
14 HIDE, G., BUCHANAN, N., WELBURN, S.C., MAUDLIN, I., BARRY, J.D. and TAIT, A.
15 (1991). *Trypanosoma brucei rhodesiense*: Characterization of stocks from Zambia, Kenya
16 and Uganda using repetitive DNA probes. *Experimental Parasitology*, **72**, 430-439.
17
18 HIDE, G., WELBURN, S.C., TAIT, A. and MAUDLIN, I. (1994). Epidemiological relationships
19 of *Trypanosoma brucei* stocks from South East Uganda: Evidence for different population
20 structures in human and non human trypanosomes. *Parasitology*, **109**, 95-111.
21
22 HIDE, G., TAIT, A., MAUDLIN, I. and WELBURN, S.C. (1996). The origins, dynamics and
23 generation of *Trypanosoma brucei rhodesiense* epidemics in East Africa. *Parasitology Today*,
24 **12**, 50-55.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

HIDE G., ANGUS, S., HOLMES, P.H., MAUDLIN, I. and WELBURN, S.C. (1998).
Comparison of *Trypanosoma brucei* strains circulating in an endemic and an epidemic
sleeping sickness focus. *Experimental Parasitology*. **89**, 21-29.

HIDE, G., TILLEY, A., WELBURN, S., MAUDLIN, I. and TAIT, A. (2000). *Trypanosoma
brucei*: identification of trypanosomes with genotypic similarity to human infective isolates in
tsetse isolated from a region free of human sleeping sickness. *Experimental Parasitology*. **96**,
67 – 74.

HIDE, G. and TILLEY, A. (2001) Use of mobile genetic elements as tools for molecular
epidemiology. *International Journal of Parasitology*, **31**, 599-602.

JAMONNEAU, V., GARCIA, A., RAVEL, S., CUNY, G., OURY, B., SOLANO, P.,
N'GUESSAN, P., N'DRI, L., SANON, R., FRÉZIL, J.L. and TRUC, P. (2002). Genetic
characterization of *Trypanosoma brucei gambiense* and clinical evolution of human African
trypanosomiasis in Côte d'Ivoire. *Tropical Medicine and International Health*, **7**, 610-621.

JAMONNEAU, V., RAVEL, S., GARCIA, A., KOFFI, M., TRUC, P., LAVEISSIÈRE, C.,
HERDER, S., GRÉBAUT, P., CUNY, G. and SOLANO, P. (2004a). Characterization of
Trypanosoma brucei s.l. infecting asymptomatic sleeping-sickness patients in Côte d'Ivoire: a
new genetic group? *Annals of Tropical Medicine and Parasitology*, **98**, 329-37.

1 JAMONNEAU, V., RAVEL, S., KOFFI, M., KABA, D., ZEZE, D.G., NDRI, L., SANE, B.,
2 COULIBALY, B., CUNY, G. and SOLANO, P, (2004b). Mixed infections of trypanosomes in
3 tsetse and pigs and their epidemiological significance in a sleeping sickness focus of Côte
4 d'Ivoire. *Parasitology*. **129**, 693-702.

5

6 JENNI, L., MARTI, S., SCHWEIZER, J., BETSCHART, B., LE PAGE, R.W.F., WELLS, J.M.,
7 TAIT, A., PAINDAVOINE, P., PAYS, E. and STEINERT, M. (1986). Hybrid formation between
8 African trypanosomes during cyclical transmission. *Nature* **322**, 173-175.

9

10 KILGOUR, V. and GODFREY, D.G. (1973). Isoenzymes of alanine aminotransferase as
11 possible specific characters of trypanosomes. *Transactions of the Royal Society of Tropical*
12 *Medicine and Hygiene*. **67**, 11.

13

14 KOFFI, M., SOLANO, P., BARNABÉ, C., DE MEEÛS, T., BUCHETON, B., CUNY, G. and
15 JAMONNEAU, V. (2007). Genetic characterisation of *Trypanosoma brucei* s.l. using
16 microsatellite typing: new perspectives for the molecular epidemiology of human African
17 trypanosomiasis. *Infection Genetics and Evolution*. **7**, 675-84.

18

19 KOFFI, M., DE MEEÛS, T., BUCHETON, B., SOLANO, P., CAMARA, M., KABA, D., CUNY,
20 G., AYALA, F.J. and JAMONNEAU, V. (2009). Population genetics of *Trypanosoma brucei*
21 *gambiense*, the agent of sleeping sickness in Western Africa. *Proceedings of the National*
22 *Academy of Sciences, USA*. **106**, 209-214.

23

1 MACLEAN, L., CHISI, J.E., ODIIT, M., GIBSON, W.C., FERRIS, V., PICOZZI, K. and
2 STERNBERG, J.M. (2004). Severity of human african trypanosomiasis in East Africa is
3 associated with geographic location, parasite genotype, and host inflammatory cytokine
4 response profile. *Infection and Immunity*, **72**, 7040-7044.

5

6 MACLEAN, L., ODIIT, M., MACLEOD, A., MORRISON, L., SWEENEY, L., COOPER, A.,
7 KENNEDY, P.G. and STERNBERG, J.M. (2007). Spatially and genetically distinct African
8 trypanosome virulence variants defined by host interferon-gamma response. *Journal of*
9 *Infectious Diseases*, **196**, 1620-1628.

10

11 MACLEOD, A., TURNER, C.M.R., and TAIT, A. (1997). Detection of single copy gene
12 sequences from single trypanosomes. *Molecular and Biochemical Parasitology*, **84**, 267-270.

13

14 MACLEOD, A., TURNER, C.M.R. and TAIT, A. (1999). A high level of mixed *Trypanosoma*
15 *brucei* infections in tsetse flies detected by three hypervariable minisatellites. *Molecular and*
16 *Biochemical Parasitology*, **102**, 237-248.

17

18 MACLEOD, A., TWEEDIE, A., WELBURN, S.C., MAUDLIN, I., TURNER, M.J. and TAIT, A.
19 (2000). Minisatellite marker analysis of *Trypanosoma brucei*: reconciliation of clonal,
20 panmictic and epidemic population genetic theories. *Proceedings of the National Academy of*
21 *Sciences* **97**, 13442-13447

22

1 MACLEOD, A., TURNER, C.M.R. and TAIT, A. (2001a). The detection of geographical
2 substructuring of *Trypanosoma brucei* populations by the analysis of minisatellite
3 polymorphisms. *Parasitology* **123**, 475-482.

4

5 MACLEOD, A., TAIT, A. and TURNER, C.M. (2001b). The population genetics of
6 *Trypanosoma brucei* and the origin of human infectivity. *Philosophical Transactions of the*
7 *Royal Society of London B*, **356**, 1035-1044.

8

9 MACLEOD, A., WELBURN, S., MAUDLIN, I., TURNER, C.M. and TAIT, A. (2001c). Evidence
10 for multiple origins of human infectivity in *Trypanosoma brucei* revealed by minisatellite
11 variant repeat mapping. *Journal of Molecular Evolution* **52**, 290-301.

12

13 MATHIEU-DAUDÉ, F. and TIBAYRENC, M. (1994). Isozyme variability of *Trypanosoma*
14 *brucei* s.l.: genetic, taxonomic, and epidemiological significance. *Experimental Parasitology*,
15 **78**, 1-19.

16

17 MATHIEU-DAUDE, F., STEVENS, J., WELSH, J., TIBAYRENC, M. and MCLELLAND, M.
18 (1995). Genetic diversity and population structure of *Trypanosoma brucei*: clonality versus
19 sexuality. *Molecular and Biochemical Parasitology* **72**, 89-101.

20

21 MAYNARD SMITH, J., SMITH, N.H., O'ROURKE, M. and SPRATT, B.G. (1993). How clonal
22 are bacteria? *Proceedings of the National Academy of Sciences* **90**, 4384-4388.

23

1 MEHLITZ, D., ZILLMANN, U., SCOTT, C.M., AND GODFREY, D.G.(1982). Epidemiological
2 studies on the animal reservoir of Gambiense sleeping sickness. Part III. Characterization of
3 trypanozoon stocks by isoenzymes and sensitivity to human serum. *Tropenmedezin und*
4 *Parasitologie*, **33**, 113-118.

5

6 MILES, M.A., TOYE, P.J., OSWALD, SC. and GODFREY, D.G. (1977). The identification by
7 isoenzyme patterns of two distinct strain-groups of *Trypanosoma cruzi*, circulating
8 independently in a rural area of Brazil. *Transactions of the Royal Society of Tropical Medicine*
9 *and Hygiene*. **71**, 217-225.

10

11 MORRISON, L.J., MCCORMACK, G., SWEENEY, L., LIKEUFACK, A.C., TRUC, P.,
12 TURNER, C.M., TAIT, A. and MACLEOD, A. (2007). Use of multiple displacement
13 amplification to increase the detection and genotyping of trypanosoma species samples
14 immobilized on FTA filters. *American Journal of Tropical Medicine and Hygiene*, **76**,1132-
15 1137.

16

17 MORRISON, L.J., TAIT, A., MCCORMACK, G., SWEENEY, L., BLACK, A., TRUC, P.,
18 LIKEUFACK, A.C., TURNER, C.M. and MACLEOD, A. (2008). *Trypanosoma brucei*
19 *gambiense* Type 1 populations from human patients are clonal and display geographical
20 genetic differentiation. *Infection Genetics and Evolution*, **8**, 847-54.

21

22 NJIOKOU, F., LAVEISSIÈRE, C., SIMO, G., NKININ, S., GRÉBAUT, P., CUNY, G. and
23 HERDER, S. (2006). Wild fauna as a probable animal reservoir for *Trypanosoma brucei*
24 *gambiense* in Cameroon. *Infection Genetics and Evolution*, **6**, 147-53.

1
2 PAINDAVOINE, P., PAYS, E., LAURENT, M., GELTMEYER, Y., LE RAY, D., MEHLITZ, D.
3 and STEINERT, M. (1986). The use of DNA hybridization and numerical taxonomy in
4 determining relationships between *Trypanosoma brucei* stocks and subspecies. *Parasitology*.
5 **92**, 31-50.
6
7 PAINDAVOINE, P., ZAMPETTI-BOSSELER, F., COQUELET, H., PAYS, E. and STEINERT,
8 M. (1989). Different allele frequencies in *Trypanosoma brucei brucei* and *Trypanosoma*
9 *brucei gambiense* populations. *Molecular and Biochemical Parasitology*, **32**, 61-71.
10
11 SIMO, G., HERDER, S., NJIOKOU, F., ASONGANYI, T., TILLEY, A. and CUNY, G. (2005).
12 *Trypanosoma brucei s.l.*: characterisation of stocks from Central Africa by PCR analysis of
13 mobile genetic elements. *Experimental Parasitology*, **110**, 353-62.
14
15 SIMO, G., ASONGANYI, T., NKININ, S.W., NJIOKOU, F. and HERDER, S. (2006). High
16 prevalence of *Trypanosoma brucei gambiense* group 1 in pigs from the Fontem sleeping
17 sickness focus in Cameroon. *Veterinary Parasitology*, **139**, 57-66.
18
19 SIMO, G., CUNY, G., DEMONCHY, R. AND HERDER, S. (2008). *Trypanosoma brucei*
20 *gambiense*: study of population genetic structure of Central African stocks using amplified
21 fragment length polymorphism (AFLP). *Experimental Parasitology*, **118**, 172-80.
22

1 STEVENS, J.R. and TIBAYRENC, M. (1995). Detection of linkage disequilibrium in
2 *Trypanosoma brucei* isolated from tsetse flies and characterized by RAPD analysis and
3 isoenzymes. *Parasitology*, **110**, 181-186.

4

5 TAIT, A. (1970a). Genetics of NADP isocitrate dehydrogenase in *Paramecium aurelia*.
6 *Nature*, **225**, 181-182.

7

8 TAIT, A. (1970b). Enzyme variation between syngens in *Paramecium aurelia*. *Biochemical*
9 *Genetics*, **4**, 461-70.

10

11 TAIT, A. (1980) Evidence for diploidy and mating in trypanosomes. *Nature* **287**, 536-538.

12

13 TAIT, A., BABIKER, E.A. and LE RAY, D. (1984). Enzyme variation in *Trypanosoma brucei*
14 ssp. I. Evidence for the subspeciation of *Trypanosoma brucei gambiense*. *Parasitology* **89**,
15 311-326.

16

17 TAIT, A., BARRY, J.D., WINK, R., SANDERSON, A. and CROWE, J.S. (1985). Enzyme
18 variation in *Trypanosoma brucei* ssp. II. Evidence for *T. b. rhodesiense* being a subset of
19 variants of *T. b. brucei*. *Parasitology*. **90**, 89-100.

20

21 TAIT, A. and TURNER, C.M.R. (1990). Genetic exchange in *Trypanosoma brucei*.
22 *Parasitology Today* **6**, 70-75.

23

1 TERRY R.S, SMITH, J.E., DUNCANSON, P. and HIDE, G. (2001). MGE-PCR: a novel
2 approach to the analysis of *Toxoplasma gondii* strain differentiation using mobile genetic
3 elements. *International Journal of Parasitology*, **31**, 155-161.

4

5 TIBAYRENC, M., KJELLBERG, F. and AYALA, F.J. (1990). A clonal theory of parasitic
6 protozoa: the population structures of *Entamoeba*, *Giardia*, *Leishmania*, *Naegleria*,
7 *Plasmodium*, *Trichomonas* and *Trypanosoma* and their medical and taxonomic
8 consequences. *Proceedings of the National Academy of Sciences*, **87**, 2414-2418.

9

10 TILLEY, A. and HIDE, G. (2001). Characterization of *Trypanosoma brucei* stocks by
11 Intergenic Region Typing. *Annals of Tropical Medicine and Parasitology*, **95**, 617-621.

12

13 TILLEY, A, WELBURN, S.C., FEVRE, E., FEIL, E.J. and HIDE, G. (2003). *Trypanosoma*
14 *brucei*: Trypanosome strain typing using PCR analysis of mobile genetic elements (MGE-
15 PCR). *Experimental Parasitology*, **104**, 26 –32.

16

17 TRUC, P., AERTS, D., MCNAMARA, J. J., CLAES, Y., ALLINGHAM, R. LE RAY, D. and
18 GODFREY, D. G. (1992). Direct isolation *in vitro* of *Typanosoma brucei* from man and other
19 animals, and its potential value for the diagnosis of gambian trypanosomiasis. *Transactions*
20 *of the Royol Society of Tropical Medicine and Hygiene*. **86**, 627-629.

21

22 TRUC, P., RAVEL, S., JAMONNEAU, V., N'GUESSAN, P. AND CUNY, G. (2002). Genetic
23 variability within *Trypanosoma brucei gambiense*: evidence for the circulation of different

1 genotypes in human African trypanosomiasis patients in Côte d'Ivoire. *Transactions of the*
2 *Royal Society of Tropical Medicine and Hygiene*, **96**, 52-55.

3

4 TURNER, C.M., MCLELLAN, S., LINDERGARD, L.A., BISONI, L., TAIT, A. and MACLEOD
5 A. (2004). Human infectivity trait in *Trypanosoma brucei*: stability, heritability and relationship
6 to SRA expression. *Parasitology*. **129**, 445-454

7

8 WALLIKER, D., CARTER, R. and MORGAN, S. (1971). Genetic recombination in malaria
9 parasites. *Nature*, **232**, 561-562.

10

11 WALLIKER, D., CARTER, R. and MORGAN, S. (1973). Genetic recombination in
12 *Plasmodium berghei*. *Parasitology*. **66**, 309-320.

13

14 WELBURN, S.C., PICOZZI, K., FÈVRE, E.M., COLEMAN, P.G., ODIIT, M., CARRINGTON,
15 M. and MAUDLIN, I. (2001). Identification of human infective trypanosomes in animal
16 reservoirs of sleeping sickness in Uganda by means of serum-resistance-associated (SRA)
17 gene. *The Lancet*, **358**, 2017-2019.

18

19 XONG, H.V., VANHAMME, L., CHAMEKH, M., CHIMFWEMBE, C.E., VAN DEN ABBEELE,
20 J., PAYS, A., VAN MEIRVENNE, N., HAMERS, R., DE BAETSELIER, P. and PAYS, E.
21 (1998). A VSG expression site-associated gene confers resistance to human serum in
22 *Trypanosoma rhodesiense*. *Cell*, **95**, 839-346.

23

24

1 TABLE LEGENDS

2

3 Table 1. Characteristics of the subspecies of *Trypanosoma brucei*

4

5 Table 2 Molecular epidemiological methods for analysing African trypanosomes. The table
6 shows some of the characteristics of each method: 1. Subspecies discrimination, ability to
7 discriminate between the three subspecies of *T.brucei*. 2. Identification of populations or
8 groups, the ability to define populations or groups within the subspecies. 3. Population
9 genetics, the ability to be interpreted genetically to enable population genetics to be carried
10 out. 4. Detection of mixed infections, able to detect mixed infections or not to be confounded
11 by the presence of mixed infections. 5. PCR based amplification of DNA, can be used directly
12 on blood or tissue samples without the need to amplify parasites in experimental animals or
13 *in vitro*. 6. Requires pure parasites, parasites need to be amplified and purified. MLEE,
14 Multilocus Enzyme Electrophoresis; RFLP, Restriction Fragment Length Polymorphism;
15 PCR-RFLP, PCR amplified RFLP; RAPD, Randomly Amplified Polymorphic DNA; AFLP,
16 Amplified Fragment Length Polymorphism; MGE-PCR, Mobile Genetic Element – PCR;
17 Minisatellites and Microsatellites, analysis of length polymorphism in highly repeated
18 sequences; SRA, detection of the Serum Resistance Associated gene which is found in
19 human infective *T.b.rhodesiense*.

20

21

1 FIGURE LEGEND

- 2 Figure 1 A map of the Busoga focus of *T.b.rhodesiense* sleeping sickness in Uganda. Recent
3 epidemics occurred in Tororo (1988 to date) and Soroti (1998 to date).